2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 152

Median Nerve Stiffness Measured By Elastosonography in Patients with Rheumatoid Arthritis Is Higher Than Controls
Abstract Number: 2208

Mediators of the Relationship Between Pain and Disability in the Distal Upper Limb
Abstract Number: 1255

Medicare Part B Utilization By Rheumatology Health Care Providers As Related to Population Demographics from 2013
Abstract Number: 2393

Medication Use in the Juvenile Systemic Sclerosis Inception Cohort. ARE There Differences in the Diffuse and Limited Subset Patients?
Abstract Number: 1402

Meeting the Needs of Adolescents with Autoimmune Diseases, the Development of a Clinical Transition Pathway
Abstract Number: 2993

Membrane-Type 1 Matrix Metalloproteinase Controls Osteo- and Chondrogenesis By a Proteolysis-Independent Mechanism Mediated By Its Cytoplasmic Tail
Abstract Number: 2406

Mental Health Care for Adolescents with Rheumatologic Conditions: Perspectives from Pediatric Behavioral Health Providers in North America
Abstract Number: 1869

Mental Health Care in Systemic Sclerosis; Rates of Utilization and Associated Factors in the Scleroderma Patient-Centered Intervention Network Cohort
Abstract Number: 1141

Mentoring the Pediatric Rheumatology Community through the American College of Rheumatology/Childhood Arthritis and Rheumatology Research Alliance Mentoring Interest Group Network: A Five-Year Status Update
Abstract Number: 2784

Mesenchymal Stem Cells Ameliorate Lupus By Promoting T Cell Apoptosis Via Bcl-2/Bim Independent Pathway in MRL/Lpr Mice
Abstract Number: 1844

Mesenchymal Stem Cells Ameliorate the Deficiencies in Immunomodulatory and Phagocytic Capacities of Lupus Macrophages
Abstract Number: 3176

Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies
Abstract Number: 1490

Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Abstract Number: 289

Metabolic and Inflammatory Links to Development of Rotator Cuff Tear in Hand Osteoarthritis
Abstract Number: 1828

Metabolic Reprogramming in CD4+CD28-CXCR3intt-bethi cells and Its Relevance to Pathogenesis in Patients with SLE

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].